HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation Social Bookmarking                What's this?

Effect of 3 Years of Antihypertensive Therapy on Renal Structure in Type 1 Diabetic Patients With Albuminuria

The European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT)

In the treatment of diabetic nephropathy, ACE inhibitor therapy reduces albumin excretion and slows the rate of decline in glomerular filtration rate (GFR). Our study was designed to investigate whether these effects lay in amelioration of the underlying glomerular structural abnormalities. A total of 54 type 1 diabetic patients with albuminuria and blood pressure (BP) <150/90 mmHg were randomized to receive 10 mg enalapril once daily, 10 mg nifedipine retard twice daily, or placebo in a multicenter double-blind study of 3 years’ duration. Renal biopsy was performed at baseline and follow-up, and tissue was analyzed by standard morphometric methods. BP, GFR, albumin excretion rate (AER), and HbA_1c were measured every 6 months. Enalapril lowered AER after 6 months by 26% (P < 0.05); however, this reduction was not sustained at 3 years. There was no significant effect of nifedipine or placebo on AER. GFR decreased by a similar average rate of 4.1 ml · min^–1 · year^–1 (95% CI 2.6–5.6) in all three groups. BP and HbA_1c were unchanged throughout the study in all groups. At baseline, nearly all biopsies showed classic appearances of diabetic glomerulopathy. There was no detectable effect of enalapril compared with either nifedipine or placebo on renal structure over 3 years. However, we found that patients with increased AER have established glomerulopathy and a progressive average decline in GFR of 4.1 ml · min^–1 · year^–1 in the absence of overt hypertension, and baseline AER appeared predictive of subsequent mesangial volume fraction (r² = 0.20, P = 0.0018). In this small cohort of nonhypertensive patients studied for 3 years, disease evolution appears unaffected by treatment with either enalapril or nifedipine.

Abbreviations: ACEI, ACE inhibitor; AER, albumin excretion rate; ANOVA, analysis of variance; BP, blood pressure; GBMT, glomerular basement membrane thickness; GFR, glomerular filtration rate; MGV, mean glomerular volume; Vv mat, matrix volume fraction; Vv mes, mesangial volume fraction; Vv interstitium, interstitium volume fraction

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. van den Born, B. Pisa, M. A. H. Bakker, J. W. A. M. Celie, C. Straatman, S. Thomas, G. C. Viberti, L. Kjellen, and J. H. M. Berden No Change in Glomerular Heparan Sulfate Structure in Early Human and Experimental Diabetic Nephropathy J. Biol. Chem., October 6, 2006; 281(40): 29606 - 29613. [Abstract] [Full Text] [PDF]

				Z. T. Bloomgarden Diabetic Nephropathy Diabetes Care, March 1, 2005; 28(3): 745 - 751. [Full Text] [PDF]

				M. J. Krimholtz, J. Karalliedde, S. Thomas, R. Bilous, and G. Viberti Targeting Albumin Excretion Rate in the Treatment of the Hypertensive Diabetic Patient with Renal Disease J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S42 - S47. [Abstract] [Full Text] [PDF]

				N. K. Hollenberg Treatment of the Patient With Diabetes Mellitus and Risk of Nephropathy: What Do We Know, and What Do We Need to Learn? Arch Intern Med, January 26, 2004; 164(2): 125 - 130. [Full Text] [PDF]

				I. Hajjar and T. A. Kotchen Trends in Prevalence, Awareness, Treatment, and Control of Hypertension in the United States, 1988-2000 JAMA, July 9, 2003; 290(2): 199 - 206. [Abstract] [Full Text] [PDF]

				T. M. Wendt, N. Tanji, J. Guo, T. R. Kislinger, W. Qu, Y. Lu, L. G. Bucciarelli, L. L. Rong, B. Moser, G. S. Markowitz, et al. RAGE Drives the Development of Glomerulosclerosis and Implicates Podocyte Activation in the Pathogenesis of Diabetic Nephropathy Am. J. Pathol., April 1, 2003; 162(4): 1123 - 1137. [Abstract] [Full Text] [PDF]

				K. E. White, R. W. Bilous, S. M. Marshall, M. El Nahas, G. Remuzzi, G. Piras, S. De Cosmo, and G. Viberti Podocyte Number in Normotensive Type 1 Diabetic Patients With Albuminuria Diabetes, October 1, 2002; 51(10): 3083 - 3089. [Abstract] [Full Text] [PDF]